Pfizer reported a strong sales performance for its antifungal drug Cresemba in the Asia Pacific and China, thanks to a ...

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

Super-high-yield stocks often deliver heaps of passive income early on, but they aren't famous for rapid payout raises.

Jefferies reaffirms its Buy rating on Pfizer and sticks to a $33 target, calling the stock undervalued at $23.35. Their ...

Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.

GC Biopharma partners with Pfizer Korea to distribute Paxlovid for COVID-19 GC Biopharma announced on the 2nd that it has signed a joint sales and distribution agreement for the oral COVID-19 ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Coronavirus is still claiming the lives of hundreds of Americans each week. According to official data released by the ...

High Paxlovid costs and prescribing barriers limit access for older adults and high-risk patients, despite continued free ...

Last month, an average of about 350 people died each week from COVID, according to data from the CDC. With available vaccines and treatments, why are people still dying?

Despite available vaccines and treatments, COVID-19 continues to cause an average of 350 deaths weekly in the U.S., according ...